样式: 排序: IF: - GO 导出 标记为已读
-
Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resection Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-14 Claire Sanson, Alice Roosen, Matthieu Faron, François Zaccarini, Amandine Maulard, Stephanie Scherier, Patricia Pautier, Alexandra Leary, Cyrus Chargari, Sophie Espenel, Catherine Genestie, Philippe Morice, Sebastien Gouy
Objective The aim of this study was to investigate the relation between the peritoneal cancer index, overall survival, and recurrence free survival, in patients with epithelial ovarian cancer. Methods Patients treated at the Gustave-Roussy Institute between December 2004 and November 2017 for advanced epithelial ovarian cancer in complete resection were included. The correlation between the peritoneal
-
Comparative study using indocyanine green and patent blue dye for sentinel lymph node biopsy in patients with early-stage cervical cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-14 Benedikt Wess, Christhardt Kohler, Andrea Plaikner, Samer El-Safadi, Thilo Schwandner, Ivo Meinhold-Heerlein, Giovanni Favero
ackground Lymphatic involvement is the most important prognostic factor in early-stage cervical cancer. Sentinel lymph node biopsy is a viable alternative to systematic lymphadenectomy and may identify metastases more precisely. Objective To compare two tracers (indocyanine green and patent blue) to detect sentinel nodes. Methods A single-center, retrospective study of women treated due to early-stage
-
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial) Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-13 Luis Chiva, Pilar Ordás, Nerea Martin-Calvo, Jose Manuel Aramendia, Luisa Sanchez Lorenzo, Alejandro Gallego Martínez, Ángel Vizcay, Jose Angel Minguez, Nabil Manzour, Daniel Vázquez-Vicente, Enrique Chacon, Teresa Castellanos, Antonio Gonzalez Martin
Background Currently, a lively debate exists within the scientific community regarding the most suitable procedure for treating stages IIIB–IVB carcinoma of the ovary, fallopian tubes, and peritoneum. The options under most consideration are primary cytoreductive surgery or neoadjuvant chemotherapy followed by interval cytoreductive surgery. Primary Objective To compare overall survival at 5 years
-
Robotic sentinel lymph node mapping with sensitive Firefly for endometrial cancer staging Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-13 Mary Katherine Anastasio, Alice Darling, Emma C Rossi
[Video 1][1] demonstrates the novel use of robotic sentinel lymph node (SLN) mapping using sensitive Firefly for endometrial cancer staging. Video 1 Video on robotic sentinel lymph node mapping with sensitive firefly for endometrial cancer staging Endometrial cancer staging includes lymph node
-
Intraepithelial tumor-infiltrating lymphocytes shape loco-regional PET/CT spread of locally advanced cervical cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-12 Mathilde Del, Claire Illac, Mathilde Morisseau, Martina Aida Angeles, Anne Ducassou, Sarah Betrian, Guillaume Bataillon, Gwenael Ferron, Elodie Chantalat, Erwan Gabiache, Alejandra Martinez
Background Data suggest an association between positron emission tomography/CT (PET/CT) metabolic metrics and tumor microenvironment in several malignancies, and a potential role of PET/CT to monitor response to immunotherapy. Objective To evaluate the correlation between tumor loco-regional extension and tumor-infiltrating lymphocyte infiltration in locally advanced cervical cancer prior to concurrent
-
Synergizing health: combined gynecological and bariatric robotic surgery for endometrial cancer in obese women Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-12 Anna Myriam Perrone, Francesco Mezzapesa, Paolo Bernante, Francesca Balsamo, Silvia Garelli, Pierandrea De Iaco
Endometrial cancer is the most common gynecological tumor, with approximately 10 200 new cases in 2022 in Italy.[1][1] Its incidence is on the rise, possibly linked to undefined factors, with many attributing it to the increasing rates of obesity in high-income countries. This is not an
-
Correspondence on “Sentinel lymph node assessment in patients with atypical endometrial hyperplasia: a systematic review and meta-analysis” by Vieira-Serna et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-11 X Mona Guo, Lauren M Lim, Koji Matsuo
We greatly appreciate the summary by Dr Vieira-Serna and colleagues on sentinel lymph nodes (SLN) and endometrial intra-epithelial neoplasia.[1][1] Their conclusion was that SLN assessment is safe and feasible in endometrial intra-epithelial neoplasia and “routine SLN evaluation may not be
-
Response to: Correspondence on “Sentinel lymph node assessment in patients with atypical endometrial hyperplasia: a systematic review and meta-analysis” by Vieira-Serna et al and Restaino et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-11 Santiago Vieira-Serna, David Viveros-Carreño, Rene Pareja
We appreciate the comments by Guo et al and Restaino et al on our paper.[1][1] We concur that the gynecologic oncology community has not yet established a universally accepted threshold to determine whether the sentinel lymph node metastasis rate warrants lymph node evaluation in patients with low-
-
Correspondence on ‘Sentinel lymph node assessment in patients with atypical endometrial hyperplasia: a systematic review and meta-analysis’ by Vieira-Serna et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-11 Stefano Restaino, Martina Arcieri, Giuseppe Vizzielli
We thank the authors for this well written meta-analysis.[1][1] The topic is of great interest, and there are currently no guidelines regarding the assessment of sentinel lymph node (SNL) in this setting. The authors focused on the rate of positive lymph nodes in cases of hyperplasia or carcinoma in
-
Correspondence on “Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods” by Navarro Santana et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-09 Vincent Lavoue, Lobna Ouldamer, Cyrille Huchon
Although we congratulate Navarro Santana et al for their work entitled ‘Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods’,[1][1] some limitations have to be addressed—namely, lack of distinction between upfront surgical treatment and interval debulking
-
Response to: Correspondence on “Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods” by Lavoue et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-09 Beatriz Navarro Santana, David Viveros-Carreño, Pedro T Ramirez
We wish to thank Lavoue and colleagues for their letter[1][1] regarding our article ‘Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods’.[2][2] We agree that one limitation of our meta-analysis is the fact that we do not differentiate between primary and interval
-
Outcomes of patients with early stage mucinous ovarian carcinoma: a Dutch population-based cohort study comparing expansile and infiltrative subtypes Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-09 Marc Daniël Algera, Koen K Van de Vijver, Willemien J van Driel, Brigitte F M Slangen, Fabienne C Lof, Maaike van der Aa, R F P M Kruitwagen, Christianne A R Lok
Objective This study aimed to assess the outcomes of patients with early stage mucinous ovarian carcinoma based on subtype (expansile vs infiltrative). Methods We retrospectively analyzed all surgically treated patients with mucinous ovarian carcinoma in the Netherlands (2015–2020), using data from national registries. Subtypes were determined, with any ambiguities resolved by a dedicated gynecologic
-
Pitfalls in identifying intronic germline pathogenic variants by comprehensive cancer genomic profiling: technical limitations or biased clinical/diagnostic utility? Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-09 Maria De Bonis, Camilla Nero, Giovanni Scambia, Nicola Normanno, Angelo Minucci
Comprehensive cancer genomic profiling is currently adopted to characterize metastatic cancer patients with the aim of assessing actionable variants (ie, actionable variants in genes such as EGFR, EML4-ALK , BRAF , FGFR2 , and NTRK1/2/3 ).[1][1] Moreover, it allows the identification of potentially
-
Response to: Correspondence on ‘The Cukurova score in the prediction of primary cytoreduction in ovarian cancer’ by Verit et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-07 Ghanim Khatib
We have carefully read the letter by Verit and Bese[1][1] in response to our article on the Cukurova score in the prediction of primary cytoreduction in ovarian cancer.[2][2] The authors stated that it was not clear how the parameters were scored in the model, because a statistically significant
-
The beginning of the end for cervical cancer in India Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-07 Aarthi S Jayraj, Seema Singhal
Taking a huge step towards the goal of elimination of cervical cancer, India is getting ready to roll out its indigenous quadrivalent human papillomavirus (HPV) vaccine named Cervavac as a part of the universal immunization program. This began with the National Technical Advisory Group on
-
Correspondence on ‘The Cukurova score in the prediction of primary cytoreduction in ovarian cancer’ by Khatib et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-07 Fatma Ferda Verit, Tugan Bese
We have read the article by Khatib et al that aimed to show a new scoring system for optimal cytoreduction in advanced ovarian cancer patients.[1][1] In this scoring system, the authors also included diagnostic video assisted thorascopic surgery in some patients to improve predictability. However,
-
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-06 Tine Ottenbourgs, Toon van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys, Frédéric Selle, Inge Baas, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
Background Low-grade serous and endometrioid ovarian cancers and adult-type granulosa cell tumors are rare ovarian malignancies that show high estrogen receptor positivity. Recurrences of these subtypes of ovarian cancer are often treated with conventional chemotherapy, although response rates are disappointing. Primary Objective To determine the overall response rate of the combination therapy of
-
Delivery of hereditary cancer genetics services to patients newly diagnosed with ovarian and endometrial cancers at three gynecologic oncology clinics in the USA, Brazil, and Mexico Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-06 Erica M Bednar, Keiry A Paiz, Karen H Lu, Aline Patricia Soares Dias De Souza, Gabriela Oliveira, Carlos e Eduardo Mattos da Cunha Andrade, Lenny Gallardo, Jairo Rubio-Cordero, David Cantu-de-León, Jose Alejandro Rauh-Hain
Objective Three gynecologic oncology clinics located in the USA, Brazil, and Mexico collaborated to evaluate their delivery of hereditary cancer genetics services. This descriptive retrospective review study aimed to establish baseline rates and timeliness of guideline-recommended genetics service delivery to patients with ovarian, fallopian tube, primary peritoneal (ovarian), and endometrial cancers
-
Cardiophrenic and costophrenic lymphadenectomy in advanced ovarian cancer by prediaphragmatic subxiphoid approach: PS technique Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-06 Paul I Stanciu
Cardiophrenic and costophrenic lymphadenectomy is part of the maximal cytoreductive effort in advanced ovarian cancer and, in selected cases, could significantly improve Progression Free Survival (PFS) and Overall Survival (OS).[1][1] If complete intra-abdominal cytoreduction is achievable,
-
Surgery for gynecological cancers in the era of personalized medicine: a novel paradigm Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Christina Fotopoulou, Ane Gerda Eriksson, Glauco Baiocchi, Oliver Zivanovic
Surgery has been the cornerstone of treatment for most gynecological malignancies for centuries. In the beginning of the 19th century, the pioneers of gynecological oncologic surgery marked the path that we still follow many years later. Dr Ephraim McDowell performed the world’s first ovarian
-
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Inge Peters, Claudia Marchetti, Giovanni Scambia, Anna Fagotti
Precision medicine through molecular profiling has taken a prominent role in the treatment of solid tumors and it is widely expected that this will continue to expand. With respect to gynecological cancers, a major change has particularly been observed in the treatment landscape of epithelial ovarian, endometrial, and cervical cancers. Regarding the former, maintenance therapy with either poly(ADP-ribose)
-
Staging by imaging in gynecologic cancer and the role of ultrasound: an update of European joint consensus statements Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Daniela Fischerova, Carolina Smet, Umberto Scovazzi, Diana Natacha Sousa, Kristina Hundarova, Ingfrid Salvesen Haldorsen
In recent years the role of diagnostic imaging by pelvic ultrasound in the diagnosis and staging of gynecological cancers has been growing exponentially. Evidence from recent prospective multicenter studies has demonstrated high accuracy for pre-operative locoregional ultrasound staging in gynecological cancers. Therefore, in many leading gynecologic oncology units, ultrasound is implemented next to
-
Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go? Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Ryan M Kahn, Suk-Joon Chang, Dennis S Chi
Complex surgery is an essential component in the management of advanced ovarian cancer. Furthermore, achieving complete gross resection in cytoreductive surgery appears to be associated with significant survival benefits in patients with advanced ovarian cancer. The goal of this review is to demonstrate the advancement of surgical techniques in gynecologic oncology surgery, including resection of disease
-
De-escalation of surgical radicality for non-fertility preserving management in patients with early-stage cervical cancer: a systematic review Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 David Viveros-Carreño, Rene Pareja, Marie Plante
Objective We sought to evaluate the oncologic outcomes of simple hysterectomy in patients with low-risk early-stage cervical cancer (tumors ≤2 cm with limited stromal invasion). Methods This study was registered in PROSPERO (registration number CRD42023433840) following the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) checklist. MEDLINE (through Ovid), EmMBASEbase, and
-
Gynecological sarcomas, surgical management: primary, metastatic, and recurrent disease Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Gwenael Ferron, Guillaume Bataillon, Alejandra Martinez, Frederic Chibon, Thibaud Valentin
Adult-type gynecological soft tissue and visceral sarcomas are rare tumors, with an estimated incidence of 13% of all sarcomas and 4% of all gynecological malignancies. They most often develop in the uterus (83%), followed by the ovaries (8%), vulva and vagina (5%), and other gynecological organs (2%). The objective of this review is to provide an overview of the current management of gynecological
-
Uterine transposition for fertility preservation in pelvic cancers Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Reitan Ribeiro, Glauco Baiocchi, Andreas Obermair, Caroline Nadai Costa, Mario Leitao
Objective To review rates of uterine preservation and gonadal function, surgical outcomes, and pregnancy outcomes in patients undergoing surgical uterine transposition. Methods A structured search and analysis of the published literature on uterine transposition was conducted. Information on study type, sample size, patient characteristics, clinical indications, details of the surgical technique, trans-operative
-
The role of surgery in gestational trophoblastic disease: an overview Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Joseph S Ng, Arunachalam Ilancheran
Gestational trophoblastic disease comprises a group of rare, and potentially malignant, conditions that arise from abnormal trophoblastic proliferation. When there is invasion and evidence of metastatic disease, gestational trophoblastic neoplasia is used. While chemotherapy is the mainstay of treatment for gestational trophoblastic neoplasia, the role of surgery has come full circle in recent years
-
Update on near infrared imaging technology: indocyanine green and near infrared technology in the treatment of gynecologic cancers Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Beryl Manning-Geist, Andreas Obermair, Vance A Broach, Mario M Leitao, Oliver Zivanovic, Nadeem R Abu-Rustum
In 2020, we published a comprehensive update on the use of fluorescence imaging systems in gynecologic cancer surgery.[1][1] The objective of the current review is to present recent advances in the use of near-infrared (NIR) imaging with indocyanine green (ICG) specific to ureter visualization,
-
The art of bowel surgery in gynecologic cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Enrique Chacon, Luis Chiva
The field of gynecologic oncology has witnessed a profound transformation in the practice of bowel resection over the years. This evolution, driven by innovative techniques and expanded surgical skills, has redefined the role of the surgeon. This review article delves into the historical journey of bowel surgery, its contemporary importance in cytoreductive procedures for gynecologic cancers, and the
-
Trends and current aspects of reconstructive surgery for gynecological cancers Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Matteo Loverro, Alessia Aloisi, Lucia Tortorella, Giovanni Damiano Aletti, Amanika Kumar
Gynecologic cancers can lead to gynecologic tract destruction with extension into both the gastrointestinal and urinary tracts. Recurrent disease can also affect the surrounding bony pelvis and pelvic musculature. As opposed to advanced ovarian cancer, where cytoreduction is the goal, in these scenarios, an oncologic approach to achieve negative margins is critical for benefit. Surgeries aimed at achieving
-
Surgical options for lymphedema after gynecological cancer treatment: current trends and advances Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Bernardo Pinheiro de Senna Nogueira Batista, Edward I-Fei Chang
Lower leg lymphedema is an important complication after gynecological treatment that can severely affect the quality of life of long-term survivors of these malignancies. As a chronic and progressive disease, affected patients will require life-long therapy centered on compression. Although conventional compressive treatments can be effective, they are extremely burdensome and time-consuming for most
-
Health-related quality of life metrics as endpoints in surgical trials: hype or hope? Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Robert Armbrust, Jennifer Davies-Oliveira, Jalid Sehouli
The management of gynecological cancer has evolved considerably over the past decades in almost every field of treatment. Surgery plays a major role in the treatment algorithm. However, these invasive interventions can have profound implications for the quality of life (QoL) of affected individuals. The routine implementation of QoL measurements in clinical trials has become common, reflecting a new
-
Medicolegal, infrastructural, and financial aspects in gynecologic cancer surgery and their implications in decision making processes: Quo Vadis? Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Emma Allanson, Anjali Hari, Edgard Ndaboine, Paul A Cohen, Robert Bristow
Surgical decision making is complex and involves a combination of analytic, intuitive, and cognitive processes. Medicolegal, infrastructural, and financial factors may influence these processes depending on the context and setting, but to what extent can they influence surgical decision making in gynecologic oncology? This scoping review evaluates existing literature related to medicolegal, infrastructural
-
Physical and psychological impact of surgery on the operating surgeon Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Anumithra Amirthanayagam, Seth O'Neill, Charles Goss, Esther L Moss
The impact of surgery on the surgeon’s well-being encompasses both physical and psychological aspects. Physically, surgeons are at risk of work-related musculoskeletal symptoms due to the nature of their work, and this risk can be impacted by theater environment, equipment design, and workload. Many symptoms will be self-limiting, but work related musculoskeletal symptoms can lead to the development
-
Incidence of venous thromboembolism in patients with ovarian cancer receiving neoadjuvant chemotherapy: systematic review and meta-analysis Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Kristin Ashley Black, Sylvie Bowden, Pamela Chu, Caitlin McClurg, Sophia Pin, Amy Metcalfe
Objective Venous thromboembolism is associated with significant patient morbidity, mortality, and can lead to delays in treatment for patients with cancer. The objectives of this study were to identify the incidence of venous thromboembolism in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy, and identify risk factors for venous thromboembolism. Methods A systematic literature
-
Mismatch repair status and surgical approach in apparent early-stage endometrial cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Rhett Morton, Penelope M Webb, Renhua Na, Andreas Obermair, Rhonda Farrell
Objective To test the hypothesis that mismatch repair (MMR) status (as an accurate surrogate marker for microsatellite stability) modifies the effect of surgical approach on oncological outcome for apparent early-stage endometrial cancer. Methods Observational data from a large prospective population study on endometrial cancer were analyzed using target trial methodology and doubly robust methods
-
Concurrent endometrial cancer in atypical endometrial hyperplasia and the role of sentinel lymph nodes: clinical insights from a multicenter experience Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-01 Andrea Rosati, Virginia Vargiu, Vito Andrea Capozzi, Diana Giannarelli, Emilia Palmieri, Alessandro Baroni, Emanuele Perrone, Roberto Berretta, Francesco Cosentino, Giovanni Scambia, Francesco Fanfani
Objective This study aimed to evaluate the prevalence of concurrent endometrial cancer in patients pre-operatively diagnosed with atypical endometrial hyperplasia undergoing hysterectomy. Additionally, we assessed the occurrence of high to intermediate-risk and high-risk tumors according to the ESGO-ESTRO-ESP classification. The study also compared surgical outcomes and complications between patients
-
Correspondence on ‘Intrauterine manipulator use during laparoscopic hysterectomy for endometrial cancer: association for pathological factors and oncologic outcomes’ by Yoshida et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-23 Pablo Padilla-Iserte, Santiago Domingo
We would like to congratulate the authors for the recent publication regarding the use of the uterine manipulator in endometrial cancer.[1][1] In this large Japanese retrospective cohort, patients had worse oncological outcomes, with higher lymphovascular space invasion (LVSI) and peritoneal
-
European Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-23 Christina Fotopoulou, Ane Gerda Eriksson, François Planchamp, Philippe Morice, Alexandra Taylor, Alina Sturdza, Ovidiu Florin Coza, Michael J Halaska, Fabio Martinelli, Robert Armbrust, Cyrus Chargari
Although the incidence of cervical cancer in Europe is declining it remains a major public health problem, particularly in limited-resourced countries, with wide variations in regional and national management. Cervical cancer is still the leading cause of cancer-related death in women in eastern,
-
Benign Brenner tumor pathology: the ‘dragon fruit sign’ Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-22 Paytra A Klein, Amelia Stapleton Van Doren, Johanna Bringley
Eponymophilia is the practice of naming a medical condition or pathological finding after a person, place, or thing, such as Alzheimer’s disease, Coxsackie virus, or pearls-on-a-string sign.[1][1] The field of obstetrics and gynecology, in particular, has a rich history of eponym usage.[2][2]
-
Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-22 Duco H K Gaillard, Pien Lof, Erik A Sistermans, Tom Mokveld, Hugo Mark Horlings, Constantijne H Mom, Marcel J T Reinders, Frédéric Amant, Daan van den Broek, Lodewyk F A Wessels, Christianne A R Lok
Objective To assess the feasibility of scalable, objective, and minimally invasive liquid biopsy-derived biomarkers such as cell-free DNA copy number profiles, human epididymis protein 4 (HE4), and cancer antigen 125 (CA125) for pre-operative risk assessment of early-stage ovarian cancer in a clinically representative and diagnostically challenging population and to compare the performance of these
-
Mirvetuximab soravtansine: an oasis in the desert? Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-22 Luisa Bonilla, Lawrence Kasherman, Luis Manso, Ainhoa Madariaga
Three common facts arise in discussions about ovarian cancer nowadays. First, systemic therapy was introduced approximately five decades ago and remained largely unchanged for four of those decades. Second, only a fraction of patients possess a reliable predictive marker of response to therapy,
-
Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-22 Amy Jamieson, Marcel Grube, Samuel Leung, Derek Chiu, Amy Lum, Janice S Kwon, Aline Talhouk, Blake Gilks, Stefan Kommoss, Jessica N McAlpine
Objectives Optimal management of patients with stage IA p53abn endometrial cancer without myoinvasion, classified as intermediate risk in the 2020 European Society of Gynaecological Oncology, European Society for Radiotherapy and Oncology, and European Society of Pathology (ESGO-ESTRO-ESP) guidelines, and the 2022 European Society of Medical Oncology (ESMO) guidelines, is currently unclear. Practice
-
Establishing guidelines for sentinel lymph node ultrastaging in endometrial cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-22 Sarah Chiang, Basile Tessier-Cloutier, Eric Klein, Orly Ardon, Jennifer J Mueller, Mario M Leitao, Nadeem R Abu-Rustum, Lora H Ellenson
Background Many sentinel lymph node (SLN) ultrastaging protocols for endometrial cancer exist, but there is no consensus method. Objective This study aims to develop guidelines for size criteria in SLN evaluation for endometrial cancer, to determine whether a single cytokeratin AE1:AE3 immunohistochemical slide provides sufficient data for diagnosis, and to compare cost efficiency between current and
-
Consensus on surgical technique for sentinel lymph node dissection in cervical cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-20 Nicolò Bizzarri, Andreas Obermair, Heng-Cheng Hsu, Enrique Chacon, Anna Collins, Irina Tsibulak, Alex Mutombo, Nadeem R Abu-Rustum, Vincent Balaya, Alessandro Buda, David Cibula, Allan Covens, Francesco Fanfani, Gwenaël Ferron, Michael Frumovitz, Benedetta Guani, Roman Kocian, Christhardt Kohler, Eric Leblanc, Fabrice Lecuru, Mario M Leitao, Patrice Mathevet, Michael D Mueller, Andrea Papadia, Rene
Objective The purpose of this study was to establish a consensus on the surgical technique for sentinel lymph node (SLN) dissection in cervical cancer. Methods A 26 question survey was emailed to international expert gynecological oncology surgeons. A two-step modified Delphi method was used to establish consensus. After a first round of online survey, the questions were amended and a second round
-
Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-20 Ana Luzarraga Aznar, Vicente Bebia, Carlos López-Gil, Beatriz Villafranca-Magdalena, Lourdes Salazar-Huayna, Josep Castellvi, Eva Colàs, Antonio Gil-Moreno, Silvia Cabrera
Objectives To investigate the pattern of first recurrence of disease in patients with endometrial cancer according to molecular classification, and to assess the independent role of molecular profiling in each type of failure. Methods Retrospective single-center study including patients diagnosed with endometrial cancer stage I–IVB (International Federation of Gynecology and Obstetrics 2009) between
-
Gynecologic oncology surgeons driving environmental and economic impact reduction Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-16 Santiago Scasso, Joel Laufer, Diego Arena, Marcos Trinidad, Walter Pereyra
The current generation is witnessing the environmental repercussions brought on by human actions, necessitating urgent global efforts. The healthcare system, responsible for 4.9% of global carbon emissions, demands targeted interventions. Notably, operating rooms contribute significantly to
-
The International Gynecologic Cancer Society Preinvasive Certificate Program: building a skilled workforce for the detection and treatment of cervical pre-cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-12 Karen Haney, Ida Ismail-Pratt, Joseph Soon-Yau Ng, Kathleen M Schmeler, Mila Pontremoli Salcedo
Cervical cancer is preventable, yet annual global incidence and mortality rates remain unacceptably high. In 2020, the World Health Organization (WHO) adopted the Global Strategy for cervical cancer elimination with a central goal of screening and treating women with cervical pre-cancer and cancer.
-
Financial toxicity in gynecologic oncology: a multi-practice survey Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-12 Anna Jo Smith, Maya H Sharma, Kristina Powell, Meredith Doherty, Stefanie N Hinkle, Emily Meichun Ko
Background Financial toxicity is associated with worse cancer outcomes, including lower survival. Objective To characterize the prevalence of, and patient risk factors for, financial toxicity among gynecologic oncology patients in a multi-site health system. Methods We identified patients seen in University of Pennsylvania gynecologic oncology practices between January 2020 and February 2022 with a
-
Assessment of sentinel Lymph node mapping with different volumes of Indocyanine green in early-stage ENdometrial cancer: the ALIEN study Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-08 Jessica Mauro, Diego Raimondo, Giampaolo Di Martino, Maria Luisa Gasparri, Stefano Restaino, Daniele Neola, Luca Clivio, Carmelo Calidona, Robert Fruscio, Giuseppe Vizzielli, Stefano Uccella, Andrea Papadia, Renato Seracchioli, Alessandro Buda
Objective To evaluate the impact of different volumes of indocyanine green (ICG) on the detection rate and bilateral mapping of sentinel lymph nodes in patients with apparent uterine-confined endometrial cancer. Methods All patients who underwent surgical staging with sentinel node mapping in six reference centers were included. Two different protocols of ICG intracervical injection were used: (1)
-
Role of endometrial sampling to differentiate between advanced endometrial versus ovarian malignancy: retrospective cohort study Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-08 Nguyen Thao Thi Nguyen, Nicole Diaz, Hadley Reid, Rebecca Previs, Laura J Havrilesky, Angeles Alvarez Secord, Andrew Berchuck
Objective Distinguishing between advanced stage endometrial and ovarian cancer at diagnosis can be challenging, especially when patients do not present with abnormal uterine bleeding. Given emerging systemic therapies specific for ovarian versus endometrial cancers, it has become increasingly critical to establish the correct diagnosis at presentation to ensure appropriate treatment. This study evaluates
-
A computer synoptic operative report versus a report dictated by a surgeon in advanced ovarian cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-08 Alice Bedel, Guillaume Blache, Camille Jauffret, Gilles Houvenaeghel, Max Buttarelli, Laura Sabiani, Navid Mokarram Dorri, Houssein El Hajj, Eric Lambaudie
Objective To evaluate the role of a computer synoptic operative report in enhancing the quality and completeness of surgical reporting for advanced ovarian cancer surgeries. Methods The study was conducted at a tertiary cancer center between January 2016 and September 2021, and the computer synoptic operative report was implemented in May 2019. The study compared two cohorts: the first consisted of
-
Intrauterine manipulator use during laparoscopic hysterectomy for endometrial cancer: association for pathological factors and oncologic outcomes Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-08 Hiroshi Yoshida, Koji Matsuo, Hiroko Machida, Shinya Matsuzaki, Michihide Maeda, Yoshito Terai, Takuma Fujii, Masaki Mandai, Kei Kawana, Hiroaki Kobayashi, Mikio Mikami, Satoru Nagase
Objective To examine the association between intrauterine manipulator use and pathological factors and oncologic outcomes in patients with endometrial cancer who had laparoscopic hysterectomy in Japan. Methods This was a nationwide retrospective cohort study of the tumor registry of the Japan Society of Obstetrics and Gynecology. Study population was 3846 patients who had laparoscopic hysterectomy
-
Conservative management of burst adbomen after interval cytoreduction surgery of ovarian carcinosarcoma Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-07 Alberto Rafael Guijarro-Campillo, Victor Lago, Salvador Pous-Serrano, Santiago Domingo
### Highlights Laparotomy is a common procedure in patients with extended carcinomatosis disease. A burst abdomen is an exceptional complication in midline laparotomies, reported in 0.2% to 5%[1][1] after elective surgery and 8.5% to 45%[2][2] after emergency surgery. This scenario is associated
-
Robotic-assisted versus conventional laparoscopic surgery in the management of obese patients with early endometrial cancer in the sentinel lymph node era: a randomized controlled study (RObese) Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-07 Giorgia Dinoi, Vincenzo Tarantino, Nicolò Bizzarri, Emanuele Perrone, Ilaria Capasso, Diana Giannarelli, Denis Querleu, Maria Consiglia Giuliano, Anna Fagotti, Giovanni Scambia, Francesco Fanfani
Background Nearly 65% of patients with endometrial cancer who undergo primary hysterectomy have concurrent obesity. Retrospective data show advantages in using robotic surgery in these patients compared with conventional laparoscopy, namely lower conversion rate, increased rate of same-day discharge, and reduced blood loss. Nevertheless, to date no prospective randomized controlled trials have compared
-
Attitude of BRCA1/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-01 Chen Nahshon, Yakir Segev, Meirav Schmidt, Ofer Lavie
Objective To study and quantify the attitude of BRCA1/2 mutation carriers towards surgical risk reduction procedures. Methods This cross-sectional national study was conducted by distribution of an anonymous questionnaire on social media platforms and to BRCA1/2 carriers’ medical clinic. Results 530 BRCA1/2 mutation carriers answered the survey. Risk reduction bilateral salpingo-oophorectomy was discussed
-
Development and clinical application of a tool to identify frailty in elderly patients with gynecological cancers Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-01 Annamaria Ferrero, Roberta Massobrio, Michela Villa, Enrico Badellino, Jeremy Oscar Smith Pezua Sanjinez, Margherita Giorgi, Alessandra Testi, Francesca Govone, Daniela Attianese, Nicoletta Biglia
Objective Frailty is more reliable than chronological age in predicting the effectiveness and tolerability of treatments in cancer patients. An increasing number of screening tools have been proposed, however none have received unanimous consent or been specifically designed for women with gynecological malignancies. This study’s aim was to develop a clinical application of a screening tool to identify
-
A new, less invasive approach for retroperitoneal pelvic and para-aortic lymphadenectomy combining the transvaginal natural orifice transluminal endoscopic surgery (vNOTES) technique and single-port laparoscopy Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-05 Behzat Can, Sedat Akgöl, Özgür Adıgüzel, Cihan Kaya
Transvaginal natural orifice transluminal endoscopic surgery (vNOTES) is a safe and feasible technique. It broadens the indications of conventional vaginal surgery.[1][1] Recently, a new retroperitoneal sentinel lymph node biopsy via the vNOTES approach was defined for endometrial cancer patients.[
-
Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-01 Giuseppe Cucinella, Gabriella Schivardi, Xun Clare Zhou, Mariam AlHilli, Sumer Wallace, Christoph Wohlmuth, Glauco Baiocchi, Nedim Tokgozoglu, Francesco Raspagliesi, Alessandro Buda, Vanna Zanagnolo, Ignacio Zapardiel, Nisha Jagasia, Robert Giuntoli, Ariel Glickman, Michele Peiretti, Maximilian Lanner, Enrique Chacon, Julian Di Guilmi, Augusto Pereira, Enora Laas-Faron, Ami Fishman, Caroline C Nitschmann
Objective The prognostic significance of isolated tumor cells (≤0.2 mm) in sentinel lymph nodes (SLNs) of endometrial cancer patients is still unclear. Our aim was to assess the prognostic value of isolated tumor cells in patients with low risk endometrial cancer who underwent SLN biopsy and did not receive adjuvant therapy. Outcomes were compared with node negative patients. Methods Patients with
-
Isolated tumor cells in low-risk endometrial cancer: are we ready for treatment decisions in ‘isolation’? Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-02-01 Heng-Cheng Hsu, Pedro T Ramirez
Low-volume disease in the lymph nodes is categorized as either micrometastases or isolated tumor cells. Does the presence of isolated tumor cell impact the decision on adjuvant treatment or not? Neither the FIGO 2009 staging nor the recently updated FIGO 2023[1][1] staging incorporates isolated